References
- Clift R. A., Appelbaum F. R., Thomas E. D. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954–1956
- Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691–703
- Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82: 398–07
- The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–825
- Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 1993; 10: 427–432
- McGlave P. B., De Fabritiis P., Deisseroth A., et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343: 1486–1488
- Talpaz M., Kantarjian H., Liang J., et al. Percentage of Philadelphia chromosome (Ph)-negative and Ph-psotive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 1995; 85: 3257–3263
- Barnett M. J., Eaves C. J., Phillips G. L., et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84: 724–732
- McGlave P. B., Arthur D., Miller W. J., Lasky L., Kersey J. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 1990; 6: 115–120
- Carlo-Stella C., Mangoni L., Almici C., et al. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14: 425–432
- Carella A. M., Podesta M., Frassoni F., et al. Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267–271
- Carella A. M., Pollicardo N., Pungolino E., et al. Mobilization of cytogenetically ‘normal’ blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leuk Lymphoma 1993; 9: 477–483
- Kantarjian H. M., Talpaz M., Hester J., et al. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. J Clin Oncol 1995; 13: 553–559
- Mehta J., Mijovic A., Powles R., et al. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. Bone Marrow Transplant 1996; 17: 25–29
- Kuss B. J., Sage R. E., Shepherd K. M., Hardingham J., Nicola M. High dose hydroxyurea in collection of Philadelphia chromosome-negative stem cells in chronic myeloid leukaemia. Leuk Lymphoma 1993; 10: 73–78
- Johnson R. J., Owen R. G., Morgan G. J., Barnard D. L., Child J. A., Smith G. M. Oral hydroxyurea (HU) and rhG-CSF (Neupogen) mobilisation of Philadelphia negative stem cells in patients with CGL. Br J Haematol 1995; 89(Suppl 1)6
- Mehta J., Powles R., Cabral S., et al. Comparison of Cobe Spectra and Haemonetics MCS-3P cell separators for peripheral blood stem cell harvesting. Bone Marrow Transplant 1995; 16: 707–709
- O'Brien S. G., Rule S., Spencer A., et al. Autografting in chronic phase CML using PBPCs mobilized by intermediate-dose chemotherapy. Br J Haematol 1995; 89(Suppl 1)39